Latest filing published 12 Nov 2015 for Supernus Pharmaceuticals, INC..
Insider track record
No signal scores available.
Closed purchases
Not enough history yet: 0 closed purchases, at least 2 are needed.
Purchases by company
New Enterprise Associates 11 LP: trading record in brief
Filings by New Enterprise Associates 11 LP span 6 companies, the busiest being Tableau Software Inc, Innerworkings Inc and Amicus Therapeutics, Inc. We count 34 filings; the first trade dates from 5 June 2007 and the latest from 11 November 2015.
On the open market, the record shows 2 purchases worth €20.7M and 8 sales worth €423.0M. The net balance comes to €402.3M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 1 share grant.
On 12 November 2015 came the latest disclosure, a transaction in Supernus Pharmaceuticals, Inc. The most recent open-market purchase was published on 8 May 2012, 5,298 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to New Enterprise Associates 11 LP
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,820,625 shares0Common StockSEC:0001209191-15-079649:0
- 3,000,000 shares0Common StockSEC:0001181431-15-008368:0
- 1,250,000 sharesClass A Common StockSEC:0001181431-14-038022:0
- 1,250,000 shares0Class A Common StockSEC:0001181431-14-038022:1
- 1,607,096 sharesClass A Common StockSEC:0001181431-14-029991:0
- 1,607,096 shares0Class A Common StockSEC:0001181431-14-029991:1
- 1,607,096 sharesClass A Common StockSEC:0001181431-14-010962:0
- 1,607,096 shares0Class A Common StockSEC:0001181431-14-010962:1
- 3,214,192 sharesClass A Common StockSEC:0001181431-14-009930:0
- 3,214,192 shares0Class A Common StockSEC:0001181431-14-009930:1
- 1,152,625 sharesClass A Common StockSEC:0001181431-13-059890:0
- 1,152,625 shares@ US$62.725Class A Common StockSEC:0001181431-13-059890:1
- 6,756,077 sharesClass A Common StockSEC:0001181431-13-059101:0
- 6,756,077 shares@ US$62.725Class A Common StockSEC:0001181431-13-059101:1
- 1,439,003 shares0Common StockSEC:0001181431-13-056691:0
- 2,239,385 shares0Common StockSEC:0001181431-13-055856:0
- 2,000,000 sharesClass A Common StockSEC:0001181431-13-030300:0
- 2,000,000 shares@ US$28.83Class A Common StockSEC:0001181431-13-030300:1
- 4,478,770 sharesCommon StockSEC:0001181431-13-012144:0
- 1,400,000 shares0Common StockSEC:0001181431-13-010858:0
- 4,278,005 sharesCommon StockSEC:0001181431-12-030204:0
- 6,241,250 sharesCommon StockSEC:0001181431-12-028420:0
- 4,400,000 shares@ US$5.00Common StockSEC:0001181431-12-028420:1Canonical exit: 2 Aug 2012 (T+90)
- 500,000 shares0Common StockSEC:0001181431-12-020684:0
- 1,000,000 shares0Common StockSEC:0001181431-12-019950:0
25 of 34 declarations